Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo

1866.157 - 1889.054 Dr. Andrea Apolo

So I love that. And the Tembola trial did that in a non-randomized fashion using ctDNA and seeing if they can treat the patients that are ctDNA positive or convert to positive with adjuvant atezolizumab and seeing if those patients did better. And the nice thing is that they showed that One of the things that was really interesting, I thought that they showed was that high risk.